AGPU AGPU Drug Discovery Services — Assets Excluding Discontinued Operations

Similar metrics at other companies

SDGRDrug Discovery Services — Drug discovery services revenue from contracts with customers

$11.7M+105%

SDGRDrug discovery contribution — Total revenues

$148K-70.3%

ARWROperating Segment — Discovery costs

$18.5M+24.9%

SDGRDrug discovery — Drug discovery services revenue from contracts with customers

$23.03M+115%

SDGRDrug discovery — Total revenues

$22.88M+124%

CWCOServices — Assets Continued Operation

$71.17M+11.8%

Questions, answered.

What is AGPU's drug discovery services — assets excluding discontinued operations?

AGPU (AGPU) reported drug discovery services — assets excluding discontinued operations of $1.7M in Q1 2026.

What does drug discovery services — assets excluding discontinued operations mean?

Represents the total value of assets held by the Drug Discovery Services segment that are expected to contribute to future economic benefits. This metric excludes assets associated with discontinued operations to provide a clear view of the segment's ongoing resource base. It is a key indicator of the capital intensity and operational scale of the drug discovery business.